Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24

The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24

The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24

Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24

Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24

Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24

Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24

Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24

Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24

Daratumumab vs Observation in High-Risk SMM (Aquila Study) | Meletios Dimopoulos, MD | #ASH24

Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24

Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24

Management and Outcomes of MGRS (Monoclonal Gammopathy of Renal Significance) | Danai Dima | #ASH24

Management and Outcomes of MGRS (Monoclonal Gammopathy of Renal Significance) | Danai Dima | #ASH24

Elranatamab + Carfilzomib: Results in Relapsed/Refractory Myeloma

Outcomes of Teclistamab in RRMM Patients Who Had Prior BCMA-Directed Therapy | Danai Dima | #ASH24

Outcomes of Teclistamab in RRMM Patients Who Had Prior BCMA-Directed Therapy | Danai Dima | #ASH24

Belentamab Plus Cyclophosphamide & Dexamethasone in RRMM (ProMMise Study) | Rakesh Popat | #ASH24

Belentamab Plus Cyclophosphamide & Dexamethasone in RRMM (ProMMise Study) | Rakesh Popat | #ASH24

MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat | #ASH24

MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat | #ASH24

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD | #ASH24

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD | #ASH24

Using whole genome sequencing to differentiate between low-risk and high-risk smoldering myeloma | Mehmet Samur, PhD | #ASH24